Lilly, Novartis Help Forma Therapeutics Raise $25 Million To Expand R&D In Asia
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Forma Therapeutics has closed a new financing venture round, which amounted to $25.5 million and was led by investors from Lilly Ventures, Novartis Option Fund and Bio*One Capital of Singapore
You may also be interested in...
Boehringer, Forma Strike Discovery Deal In Oncology
The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.
Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
The Roche-owned biotech licensed a novel oncology target from the startup, but could take outright possession of the program - with a payout for VCs.
Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
The Roche-owned biotech licensed a novel oncology target from the startup, but could take outright possession of the program - with a payout for VCs.